Amgen not willing to be taken for a ride amid soaring M&A valuations

12 February 2018

The problem with being a cash-laden big biotech company can be that everyone knows that you are a cash-laden big biotech company.

US biotech giant Amgen (Nasdaq: AMGN) is the latest to experience this, with its need to increase revenues by acquiring new assets, and its sizeable pot of money to achieve this, something that potential targets are very much aware of.

Possibly Monday’s interview piece in UK newspaper The Financial Times, titled Amgen struggles to find deal targets, will not help the situation by drawing further attention to the firm's dilemma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK